SCHEMBL8055813

SCHEMBL8055813

C1=N[C@H](c2ccccc2)CO1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 4/20 0.46
TSHR P16473 1/20 0.43
MAPT P10636 2/20 0.38
MAOB P27338 8/20 0.37
MAOA P21397 7/20 0.37
KDM1A O60341 5/20 0.37
CYP2C19 P33261 4/20 0.37
CYP2B6 P20813 3/20 0.37
CYP1A2 P05177 2/20 0.37
CYP2D6 P10635 2/20 0.37
CYP2C9 P11712 2/20 0.37
LMNA P02545 2/20 0.37
CYP3A4 P08684 1/20 0.37
HTR1A P08908 1/20 0.37
ADRA2A P08913 1/20 0.37
CYP2A6 P11509 1/20 0.37
SLC6A2 P23975 1/20 0.37
HTR2C P28335 1/20 0.37
ADRA1A P35348 1/20 0.37
DRD3 P35462 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL500727 1.00 TAAR1 (0.46) TAAR1TSHRMAPTMAOBMAOA
SCHEMBL3354178 1.00 TAAR1 (0.46) TAAR1TSHRMAPTMAOBMAOA
Dibenzofuran SCHEMBL28885932 0.86 TAAR1 (0.37) TAAR1TSHRMAPTMAOACYP2C9
SCHEMBL28563511 0.79 KDM1A (0.37) MAPTKDM1ACYP2C9LMNACYP3A4
SCHEMBL15842791 0.76 TAAR1 (0.35) TAAR1TSHRMAPT
SCHEMBL15842834 0.74 TAAR1 (0.33) TAAR1TSHRMAPT
SCHEMBL20385798 0.74 HTR2C (0.46) KDM1AHTR1AHTR2CDRD3RCOR1
SCHEMBL14044885 0.74 HTR2C (0.45) TAAR1KDM1ALMNAHTR2CADRA1A
SCHEMBL28867385 0.72 TAAR1 (0.51) TAAR1TSHRMAOBMAOAKDM1A
SCHEMBL20385738 0.72 TAAR1 (0.51) TAAR1TSHRMAOBMAOAKDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115894299-B Preparation method of axial chiral carbamate 华南理工大学 2024-03-12 CN claimed
US-12492194-B2 HPK1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-12-09 US disclosed
US-12486264-B2 Bicyclic HPK1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2025-12-02 US disclosed
EP-3947366-B1 HPK1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2025-05-21 EP disclosed
EP-3947373-B1 BICYCLIC HPK1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2025-05-14 EP disclosed
US-20220389157-A1 PROCESS FOR POLYMERIZING BETA-BUTYROLACTONE UNIV MUENCHEN TECH (DE) 2022-12-08 US disclosed
US-20220177458-A1 HPK1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2022-06-09 US disclosed
US-20220169644-A1 BICYCLIC HPK1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2022-06-02 US disclosed
EP-3974413-A1 ANTIDIABETIC SUBSTITUTED HETEROARYL COMPOUNDS MERCK SHARP & DOHME CORP. (US) 2022-03-30 EP disclosed
CN-105541925-B Ferrocene frame having ferrocene frame N, N ligand and its preparation method and application 中国人民解放军第四军医大学 2019-09-24 CN disclosed
CN-103003231-A Novel method for preparing phenylcyclopropylamine derivatives and use thereof for preparing ticagrelor ACTAVIS GROUP PTC EHF 2013-03-27 CN disclosed
CN-102348703-A Compounds for the treatment of metabolic disorders PROSIDION LTD 2012-02-08 CN disclosed
CN-1259322-C Asymmetric copper compound and cyclopropanation reaction with it SUMITOMO CHEMICAL CO (JP) 2006-06-14 CN disclosed
CN-1384105-A Asymmetric copper compound and cyclopropanation reaction with it SUMITOMO CHEMICAL CO (JP) 2002-12-11 CN disclosed
CN-1373116-A Process for preparing optical active chrysanthemic acid SUMITOMO CHEMICAL CO (JP) 2002-10-09 CN disclosed
US-6011169-A Process for producing optically active cyclopropanecaboxylic acid esters SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2000-01-04 US disclosed
EP-0891965-A1 Process for producing optically active cyclopropanecarboxylic acid esters SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1999-01-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12486264-B2 Bicyclic HPK1 inhibitors PCK1, PGK1, PDXK TAAR1 4646/4885TSHR 4507/4885MAPT 3982/4885
US-20220389157-A1 PROCESS FOR POLYMERIZING BETA-BUTYROLACTONE CYP17A1, HSD17B7, COASY TAAR1 4595/4885TSHR 4804/4885MAPT 1075/4885
US-20220169644-A1 BICYCLIC HPK1 INHIBITORS PCK1, PGK1, PDXK TAAR1 4646/4885TSHR 4507/4885MAPT 3982/4885
US-20220177458-A1 HPK1 INHIBITORS PGK1, PCK1, PDXK TAAR1 4709/4885TSHR 4497/4885MAPT 3343/4885
US-12492194-B2 HPK1 inhibitors PGK1, PCK1, PDXK TAAR1 4709/4885TSHR 4497/4885MAPT 3343/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.